-
公开(公告)号：US20100119612A1
公开(公告)日：2010-05-13
申请号：US12450563
申请日：2008-04-07
CPC分类号： A61K9/5123 , A61K9/1617 , A61K9/5146 , A61K9/5192
摘要： A pharmaceutical composition comprises nanoparticles comprising a core of non-crystalline drug and surface stabilizers consisting of a phospholipid and a bile salt.
摘要翻译： 药物组合物包含包含非结晶药物核心和由磷脂和胆汁盐组成的表面稳定剂的纳米颗粒。
-
2.发明申请PHARMACEUTICAL COMPOSITIONS COMPRISING NANOPARTICLES COMPRISING ENTERIC POLYMERS CASEIN 审中-公开包含肠溶聚合物的纳米颗粒的药物组合物公开(公告)号：US20100062073A1
公开(公告)日：2010-03-11
申请号：US12312525
申请日：2007-11-16
申请人： Ronald Arthur Beyerinck , Corey Jay Bloom , Marshall David Crew , Dwayne Thomas Friesen , Michael Mark Morgen , Daniel Tod Smithey
发明人： Ronald Arthur Beyerinck , Corey Jay Bloom , Marshall David Crew , Dwayne Thomas Friesen , Michael Mark Morgen , Daniel Tod Smithey
CPC分类号： A61K9/5161 , A61K9/5169 , A61K9/5192
摘要： A pharmaceutical composition comprises nanoparticles comprising a poorly water-soluble drug and an enteric polymer, and casein.
摘要翻译： 药物组合物包含包含难溶于水的药物和肠溶性聚合物和酪蛋白的纳米颗粒。
-
公开(公告)号：US20100003331A1
公开(公告)日：2010-01-07
申请号：US12261678
申请日：2009-09-03
申请人： Imran Ahmed , Leah Elizabeth Appel , Walter Christian Babcock , Dwayne Thomas Friesen , Scott Herbig , David Keith Lyon , Sheri L. Shamblin , Ravi Mysore Shanker , Daniel Tod Smithey , Steven C. Sutton , Avinash Govind Thombre , Kenneth C. Waterman , Jaymin C. Shah , Parag Suresh Shah , Peter Wisniecki , Dawn Renee Wagner
发明人： Imran Ahmed , Leah Elizabeth Appel , Walter Christian Babcock , Dwayne Thomas Friesen , Scott Herbig , David Keith Lyon , Sheri L. Shamblin , Ravi Mysore Shanker , Daniel Tod Smithey , Steven C. Sutton , Avinash Govind Thombre , Kenneth C. Waterman , Jaymin C. Shah , Parag Suresh Shah , Peter Wisniecki , Dawn Renee Wagner
IPC分类号： A61K9/14 , A61K31/501
CPC分类号： A61K9/1617 , A61K9/0004 , A61K9/1652 , A61K9/2018 , A61K9/2027 , A61K9/2031 , A61K9/2054 , A61K9/2077 , A61K9/2081 , A61K9/209 , A61K9/2846 , A61K9/5047 , A61K31/496 , A61K31/4965
摘要： A sustained release solid oral dosage form for treatment of a psychotic disorder, for example schizophrenia, in a mammal is provided, which oral dosage form comprises ziprasidone in an amount effective in treating said psychotic disorder and a pharmaceutically acceptable carrier.
摘要翻译： 提供了用于治疗哺乳动物中的精神病症例如精神分裂症的持续释放固体口服剂型，该口服剂型包含有效治疗所述精神病性障碍的量的齐拉西酮和药学上可接受的载体。
-
公开(公告)号：US08617604B2
公开(公告)日：2013-12-31
申请号：US11795747
申请日：2006-01-23
申请人： Walter Christian Babcock , Dwayne Thomas Friesen , David Kenneth Lyon , Warren Kenyon Miller , Daniel Tod Smithey
发明人： Walter Christian Babcock , Dwayne Thomas Friesen , David Kenneth Lyon , Warren Kenyon Miller , Daniel Tod Smithey
IPC分类号： A61K9/14
CPC分类号： A61K47/38 , A61K9/10 , A61K9/1652 , A61K9/1694 , C08B11/20 , C08B13/00 , C08L1/08 , C08L1/32
摘要： Pharmaceutical compositions of a low-solubility drug and lower alkanoate-, phthalate- and trimellitate esters of hydroxypropyl methyl cellulose and lower alkanoate- and succinate esters of cellulose and methyl cellulose are disclosed that provide enhanced concentrations of the drug in a use environment.
摘要翻译： 公开了一种低溶解度药物和羟丙基甲基纤维素的低级链烷酸酯，邻苯二甲酸酯和偏苯三酸酯和纤维素和甲基纤维素的低级链烷酸酯和琥珀酸酯的药物组合物，其在使用环境中提供增强的药物浓度。
-
公开(公告)号：US08974823B2
公开(公告)日：2015-03-10
申请号：US10596876
申请日：2004-12-20
CPC分类号： A61K9/1635 , A61K9/1641 , A61K9/5084
摘要： Solid compositions of low-solubility drugs and poloxamers that provide concentration enhancement when administered to an aqueous environment of use are disclosed.
摘要翻译： 公开了当施用于水性使用环境时提供浓度增强的低溶解度药物和泊洛沙姆的固体组合物。
-
6.发明申请METHODS, DOSAGE FORMS AND KITS FOR ADMINISTERING ZIPRASIDONE WITHOUT FOOD 审中-公开方法，剂型和用于管理不含食物的ZIPRASIDONE的试剂盒公开(公告)号：US20110002989A1
公开(公告)日：2011-01-06
申请号：US12920400
申请日：2009-03-04
申请人： William John Curatolo , Scott Max Herbig , Avinash Govind Thombre , Jaymin Chandrakant Shah , Sheri L. Shamblin , Timothy Lukas , William Brett Caldwell , Dwayne Thomas Friesen , David Keith Lyon , Christopher Donovan Craig
发明人： William John Curatolo , Scott Max Herbig , Avinash Govind Thombre , Jaymin Chandrakant Shah , Sheri L. Shamblin , Timothy Lukas , William Brett Caldwell , Dwayne Thomas Friesen , David Keith Lyon , Christopher Donovan Craig
IPC分类号： A61K31/496 , A61P25/00 , A61K31/724 , A61K31/717 , A61K9/22
CPC分类号： A61K31/496
摘要： The present invention provides methods, dosage forms and kits for treating with an effective amount of ziprasidone a CNS disorder in a human when the human is in a fasted state. In one embodiment, the invention relates to a method for treating a CNS disorder in a human, which method comprises administering to the human in a fasted state, a solid oral dosage form comprising an amount of ziprasidone effective to treat said CNS disorder, wherein the area under the serum concentration versus time curve (AUC0-inf) of the ziprasidone in the human subsequent to said administering is from 70% to 140% of the mean area under the ziprasidone serum concentration versus time curve (AUC0-inf) resulting from administration of a control ziprasidone immediate release oral capsule containing the same amount of ziprasidone to a cohort of humans in a fed state.
摘要翻译： 本发明提供了当人处于禁食状态时用人体中有效量的齐拉西酮治疗CNS病症的方法，剂型和试剂盒。 在一个实施方案中，本发明涉及一种用于治疗人类中枢神经系统疾病的方法，所述方法包括以禁食状态对人施用包含有效治疗所述CNS病症的量的齐拉西酮的固体口服剂型，其中 在所述给药之后，人体中齐拉西酮的血清浓度对时间曲线（AUC 0-inf）下的面积是由给药引起的齐拉西酮血清浓度对时间曲线（AUC 0-inf）的平均面积的70％至140％ 的控释齐拉昔酮立即释放口服胶囊含有相同数量的齐拉西酮至饲喂状态的人群。
-
公开(公告)号：US07736672B2
公开(公告)日：2010-06-15
申请号：US11003664
申请日：2004-12-03
IPC分类号： A61K9/14
CPC分类号： A61K9/1617 , A61K9/1635 , A61K9/1694
摘要： A process is described for producing drug-containing multiparticulates with improved stability, characterized by an improvement in one or more of chemical stability, physical stability, or dissolution stability.
摘要翻译： 描述了用于生产具有改进的稳定性的含药多颗粒的方法，其特征在于改进一种或多种化学稳定性，物理稳定性或溶解稳定性。
-
公开(公告)号：US06517866B1
公开(公告)日：2003-02-11
申请号：US09380897
申请日：1999-09-07
申请人： Mary Tanya Am Ende , William John Curatolo , Hylar Lewis Friedman , Dwayne Thomas Friesen , Scott Max Herbig , Ravi Mysore Shankar , James Blair West
发明人： Mary Tanya Am Ende , William John Curatolo , Hylar Lewis Friedman , Dwayne Thomas Friesen , Scott Max Herbig , Ravi Mysore Shankar , James Blair West
IPC分类号： A61K922
CPC分类号： A61K9/2054 , A61K9/0004 , A61K9/1652 , A61K9/2009 , A61K9/2013 , A61K9/2018 , A61K9/2886 , A61K9/5047 , A61K31/135
摘要： Sustained release dosage forms of sertraline which release sertraline at a rate between 1 mgA/hr and 40 mgA/hr. The dosage forms may exhibit an initial delay period during which sertraline is released at a rate less than 1 mgA/hr.
摘要翻译： 缓释剂量形式的舍曲林，以1mgA / hr至40mgA / hr的速率释放舍曲林。 剂型可以表现出以小于1mgA / hr的速率释放舍曲林的初始延迟期。
-
9.发明授权Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors and HMG-CoA reductase 有权胆固醇酯转移蛋白抑制剂和HMG-CoA还原酶的药物组合物公开(公告)号：US08828438B2
公开(公告)日：2014-09-09
申请号：US11920473
申请日：2006-05-22
申请人： Dwayne Thomas Friesen , Bruno Caspar Hancock , Rodney James Ketner , David Keith Lyon , James Alan Shriver Nightingale , Ravi Mysore Shanker
发明人： Dwayne Thomas Friesen , Bruno Caspar Hancock , Rodney James Ketner , David Keith Lyon , James Alan Shriver Nightingale , Ravi Mysore Shanker
CPC分类号： A61K45/06 , A61K9/1611 , A61K9/1635 , A61K9/1652 , A61K31/40 , A61K31/4706 , A61K2300/00
摘要： A solid amorphous dispersion comprises a cholesteryl ester transfer protein (CETP) inhibitor, an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMG-CoA reductase inhibitor), and a concentration enhancing polymer. At least a major portion of the CETP inhibitor in the dispersion is amorphous. The solid amorphous dispersion provides concentration-enhancement of the CETP inhibitor when administered to an aqueous use environment.
摘要翻译： 固体无定形分散体包含胆固醇酯转移蛋白（CETP）抑制剂，3-羟基-3-甲基戊二酰辅酶A还原酶（HMG-CoA还原酶抑制剂）的抑制剂和浓度增强聚合物。 分散体中CETP抑制剂的至少主要部分是无定形的。 当施用于水性使用环境时，固体无定形分散体提供CETP抑制剂的浓度增强。
-
公开(公告)号：US20100089186A1
公开(公告)日：2010-04-15
申请号：US12590141
申请日：2009-11-02
IPC分类号： G01N33/15
CPC分类号： B01D61/147 , B01D61/24 , B01D61/28 , B01D67/009 , B01D2325/36 , B01L3/50255 , B01L3/5085 , B01L2300/0829 , B01L2300/161 , B01L2400/0472 , G01N33/15 , G01N2013/006 , Y10S436/809 , Y10T436/255
摘要： A membrane-permeation test for evaluating pharmaceutical compositions is described. The method comprises the following steps: (1) providing a microporous membrane having a plurality of pores, the membrane having a feed side and a permeate side, wherein the feed side of the membrane is in fluid communication with the feed solution, and wherein the permeate side of the membrane is in fluid communication with a permeate solution; (2) administering a pharmaceutical composition to an aqueous solution to form a feed solution; and (3) measuring the concentration of drug in the permeate solution; wherein the feed side of the membrane is hydrophilic, and/or wherein the permeate solution comprises an organic fluid.
摘要翻译： 描述了用于评价药物组合物的膜渗透试验。 该方法包括以下步骤：（1）提供具有多个孔的微孔膜，所述膜具有进料侧和渗透侧，其中所述膜的进料侧与进料溶液流体连通，并且其中 膜的渗透侧与渗透液流体连通; （2）向水溶液施用药物组合物以形成进料溶液; 和（3）测量渗透液中药物的浓度; 其中所述膜的进料侧是亲水的，和/或其中所述渗透液包含有机流体。
-
-
-
-
-
-
-
-
-
搜索结果
24 条记录 (耗时 0.033 秒)
